News Release

Suven Life Sciences to Present Two Posters on Samelisant and Exhibit Booth 628 at SLEEP-2025 Conference, Seattle, USA

Hyderabad, India, 9-June-2025 - *Suven Life Sciences*, a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, today announced that it will present two posters at the SLEEP-2025 Annual Meeting, hosted by the Associated Professional Sleep Societies (APSS), taking place during June 8–11, 2025 in Seattle, USA.

Suven will showcase poster presentations featuring its investigational compound Samelisant (SUVN-G3031), novel and selective histamine H_3 receptor inverse agonist being developed for the treatment of sleep-wake disorders.

Presentation Details:

1. **9-June2025: Samelisant Phase-2 Cataplexy Study Design:**

This presentation outlines the Phase 2 study design evaluating the efficacy and safety of Samelisant in adult narcolepsy patients with cataplexy, detailing rationale, study methodology, inclusion/exclusion criteria, and clinical endpoints.

2. **11-June-2025: Samelisant Phase-2 Study Results to Treat Excessive Daytime Sleepiness (EDS) in Narcolepsy Patients:**

This presentation covers clinical results from its Phase-2 study assessing Samelisant in reducing excessive daytime sleepiness (EDS) in narcolepsy patients. The results highlight statistically significant improvements in key efficacy measures including the Epworth Sleepiness Scale (ESS), Clinical Global Impression–Severity (CGI-S) and Patient Global Impression–Change (PGI-C) scores.

Senior scientists of Suven conducting the Exhibit Booth # 628 throughout the event during 8-11th June, to be available for the meetings and discussions with clinical investigators and potential partnering companies.

The SLEEP-2025 abstracts are available at the website: https://www.sleepmeeting.org/abstract-supplements/

About Samelisant (SUVN-G3031) Phase-2 Narcolepsy Study: The Phase 2 clinical study was a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of Samelisant as a monotherapy in narcolepsy patients with and without cataplexy (ClinicalTrials.gov Identifier: NCT04072380). The study was conducted in USA and Canada. The study recruited 190 patients aged 18 - 65 years and were randomized in ratio of 1:1:1 to 2 mg Samelisant, 4 mg Samelisant, or Placebo treatment groups. The primary efficacy endpoint of this study was change in ESS total score from Baseline to Day 14. Secondary and exploratory endpoints were change in CGI-S score, CGI-C score and PGI-C score with regard to EDS and change in Maintenance of Wakefulness Test score from Baseline to Day 14.

About Samelisant (SUVN-G3031): Samelisant is a novel, potent, selective, brain penetrant, and orally active Histamine-3 (H3) receptor inverse agonist. H3 receptor blockade elevates histamine, norepinephrine, and dopamine in the brain, a potential for the treatment of EDS and cataplexy. Samelisant exhibited wake-promoting activity in orexin knock-out mice (an animal model of narcolepsy). Pre-clinical *in vitro* and *in vivo* efficacy studies, supporting neurochemical studies, pharmacokinetic studies, safety studies and Phase-1 studies in healthy subjects under US IND have been successfully completed for Samelisant.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase 3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase 2 study for EDS completed; Phase 2 study for Cataplexy and pivotal Phase 3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase 2a study completed; Placebo-controlled Phase 2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*